Protective effects of Althaea officinalis L. extract in 6-hydroxydopamine-induced hemi-Parkinsonism model: Behavioral, biochemical and histochemical evidence

Journal of Physiological Sciences

Volumn 64, Issue 3, 2014, Pages 171-176

  Rezaei, Maryam ^a   Alirezaei, Masoud ^b  

^a LORESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b LORESTAN UNIVERSITY   (Iran)

Author keywords

6 Hydroxydopamine; Althaea officinalis; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; MALONALDEHYDE; NEUROPROTECTIVE AGENT; OXIDOPAMINE; PLANT EXTRACT;

ALTHAEA; ANIMAL; ANIMAL BEHAVIOR; BRAIN; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; LIPID PEROXIDATION; MALE; MEDICINAL PLANT; METABOLISM; NERVE CELL; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; PATHOLOGY; PHYTOTHERAPY; PLANT LEAF; PSYCHOLOGY; TIME; WISTAR RAT;

ALTHAEA; ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; BRAIN; DISEASE MODELS, ANIMAL; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; OXIDOPAMINE; PARKINSONIAN DISORDERS; PHYTOTHERAPY; PLANT EXTRACTS; PLANT LEAVES; PLANTS, MEDICINAL; RATS, WISTAR; TIME FACTORS;

EID: 84901827790     PISSN: 18806546     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12576-014-0305-z     Document Type: Article

References (35)

1. Christen Y (2000) Oxidative stress and Alzheimer disease. Am J Clin Nutr 71:621S-629S
2. Henze C, Earl C, Sautter J, Schmidt N, Themann C, Hartmann A, Oertel WH (2005) Reactive oxidative and nitrogen species in the nigrostriatal system following striatal 6-hydroxydopamine lesion in rats. Brain Res 1052:97-104
3. Lees AJ, Hardy J, Revesz T (2009) Parkinson's disease. Lancet 373:2055-2066
4. Tsang AH, Chung KK (2009) Oxidative and nitrosative stress in Parkinson's disease. Biochim Biophys Acta 1792:643-650
5. Liao PC, Kuo YM, Chang YC, Lin C, Cherng CF, Yu L (2003) Striatal formation of 6-hydroxydopamine in mice treated with pargyline, pyrogallol and methamphetamine. J Neural Transm 110:487-494
6. de Lau LM, Breteler MM (2006) Epidemiology of Parkinson's disease. Lancet Neurol 5:525-535
7. Agid Y, Chase T, Marsden D (1998) Adverse reactions to levodopa: drug toxicity or progression of disease? Lancet 351:851-852
8. Ali Shah SM, Akhtar N, Akram M, Akhtar Shah P, Saeed T, Ahmed K, Asif HM (2011) Pharmacological activity of Althaea officinalis L. J Med Plants Res 5(24):5662-5666
9. Elmastaş M, Öztürk L, Gökçe I, Erenler R, Aboul-Enein HY (2004) Determination of antioxidant activity of marshmallow flower (Althaea officinalis L.). Anal Lett 37(9):1859-1869
10. Gudej J (1981) Polyphenolic compounds in Althaea officinalis leaves. Acta Pol Pharm 38:385
11. Gudej J (1988) Polyphenolic compounds in Althaea officinalis flowers. Acta Pol Pharm 45(4):340-345
12. Sutovska M, Capek P, Franova S, Joskova M, Sutovsky J, Marcinek J, Kalman M (2011) Antitussive activity of Althaea officinalis L. polysaccharide rhamnogalacturonan and its changes in guinea pigs with ovalbumine-induced airways inflammation. Bratisl Lek Listy 112(12):670-675
13. Paxinos G, Watson CR, Emson PC (1980) AChE-stained horizontal sections of the rat brain in stereotaxic coordinates. J Neurosci Methods 3:129-149
14. Fujita M, Nishino H, Kumazaki M, Shimada S, Tohyama M, Nishimura T (1996) Expression of dopamine transporter mRNA and its binding site in fetal nigral cells transplanted into the striatum of 6-OHDA lesioned rat. Brain Res Mol Brain Res 39:127-136
15. Pedrosa R, Soares-Da-Silva P (2002) Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by L-dihydroxy phenylalanine (L-DOPA) and dopamine. Br Pharmacol 137(8):1305-1313
16. Alirezaei M, Jelodar G, Niknam P, Ghayemi Z, Nazifi S (2011) Betaine prevents ethanol-induced oxidative stress and reduces total homocysteine in the rat cerebellum. J Physiol Biochem 67(4):605-612
17. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193(1):265-275
18. Subbarao KV, Richardson JS, Ang LC (1990) Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J Neurochem 55(1):342-345
19. Soto-Otero R, Me'ndez-A'lvarez E, Hermida-Ameijeiras A, Lo'pez-Real AM, Labandeira-Garcia JL (2002) Effects of (-)-nicotine and (-)-cotinine on 6-hydroxydopamine-induced oxidative stress and neurotoxicity: relevance for Parkinson's disease. Biochem Pharmacol 64:125-135
20. Borah A, Mohanakumar KP (2009) Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental Parkinsonism in rodents. J Pineal Res 47:293-300
21. Cossette M, Lecomte F, Partent A (2005) Morphology and distribution of dopaminergic neurons intrinsic to human striatum. J Chem Neuroanat 29:1-11
22. Muller T, Jugel C, Ehret R, Ebersbach G, Bengel G, Muhlack S, Klostermann F (2011) Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel. J Neural Transm 118(9):1329-1333
23. Nissinen E, Nissinen H, Larjonmaa H, Vaananen A, Helkamaa T, Reenila I, Rauhala P (2005) The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats. J Neural Transm 112(9):1213-1221
24. Schapira AHV (2008) The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease. Mov Disord 23(S3):S515-S520
25. Ravati A, Junker V, Kouklei M, Ahlemeyer B, Culmsee C, Kriegstein AR (1999) Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and rats. Eur J Pharmacol 373:21-33
26. Fahn S (2005) Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 252(4):iv37-iv42
27. Shulman LM (2000) Levodopa toxicity in Parkinson disease: reality or myth? Reality - practice patterns should change. Arch Neurol 57(3):406-407
28. Weiner WJ (2000) Is levodopa toxic? Arch Neurol 57(3):408
29. Weintraub D, Comella CL, Horn S (2008) Parkinson's disease - Part 1: pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Manag Care 14(2 Suppl):S40-S48
30. Astarloa R, Mena MA, Sanchez V, de la Vega L, de Yebenes JG (1992) Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease. Clin Neuropharmacol 15(5):375-380
31. Charles R (2006) Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur J Pharmacol 545:51-64
32. Didry N, Torck M, Pinkas M (1990) Polyphenolic compounds from the flowers of Althaea officinalis. Fitoterapia 61(3):280
33. Al-Snafi AE (2013) The pharmaceutical importance of Althaea officinalis and Althaea rosea: a review. Int J PharmTech Res 5(3):1378-1385
34. Gudej J (1991) Flavonoids, phenolic acids and coumarins from the roots of Althaea officinalis. Planta Med 57(3):284-285
35. Akhtardzhiev KH, Koleva M, Kitanov G, Ninov S (1984) Pharmacognistic study of representatives of Arum, Althaea and Hypericum species. Farmatsiya (Sofia) 34(3):1-6